Certara (CERT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Certara

NasdaqGS•Healthcare•Health Information Services

$7.74-0.20(-0.03%)Pre-market

Market Cap

$1.23B

P/S

3.0x

P/B

1.3x

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

How this company scores

WeakMetricSide Score: 43/100

Grade capped at D — Interest coverage below 1× (-0.0x) — earnings cannot cover interest. Strongest: Balance Sheet & Red Flags (13/25); weakest: Cash & Earnings Quality (8/25).

Profitability11/25

Growth11/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality8/25

Strengths

Long cash runwayLow leverageConsistent free cash flowConsistent growth

Grade capped at D

Interest coverage below 1× (-0.0x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 179.6x5y range 88.7x – 235.9x

Currently above its 5-quarter median.

P/S · 3.0x5y range 2.1x – 5.8x

Currently below its 19-quarter median.

P/B · 1.3x5y range 0.9x – 1.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 102.2% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.6x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $1.23B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $408.45M
Q. Revenue: $93.27M
TTM EBITDA: $67.18M
TTM Op. Income: $-658,000
Q. Op. Income: $-196,000
TTM Net Income: $-68.40M
Q. Net Income: $-55.27M
EPS: $-0.36
Shares Out.: $154.36M

$408.45M in TTM revenue grew 0.7% YoY, reaching $93.27M last quarter. TTM EBITDA of $67.18M and TTM operating income of $-658,000 show growth is flowing through to the bottom line. However, net income is negative at $68.40M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 1% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 12.4%
Op. Margin: -0.2%
Net Margin: -59.3%

Op. margin of -0.2% is down 9.3% YoY — costs are rising relative to revenue. Net margin at -59.3% Over the past year, operating margin is down 102% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.0x
P/B Ratio: 1.3x

P/S of 3.0x and P/B of 1.3x. Over the past year, P/E is up 0% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.40B
Cash: $184.14M
Long-Term Debt: $288.88M
Book Value: $966.51M
D/E Ratio: 0.3
Debt/EBITDA: 25.0

With $1.40B in assets and $288.88M in long-term debt, D/E is 0.3and book value is $966.51M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 5 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $10.04M
TTM Free Cash Flow: $80.39M
FCF Margin: 19.7%
FCF / Net Income: -1.2

TTM FCF of $80.39M on $10.04M in operating cash flow. The FCF / Net Income ratio of -1.2x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.